Loading...
XSTO
ORX
Market cap25mUSD
Oct 09, Last price  
6.58SEK
1D
-3.94%
1Q
-71.64%
Jan 2017
-82.50%
IPO
-92.69%
Name

Orexo AB

Chart & performance

D1W1MN
XSTO:ORX chart
P/E
—
P/S
8.89
EPS
—
Div yield, %
—
Shrs. gr., 5y
0.13%
Rev. gr., 5y
-47.69%
Revenues
26m
-95.59%
131,956,0000233,346,000236,104,000210,499,000199,614,000326,278,000429,355,000570,316,000643,338,000705,800,000643,700,000783,100,000844,800,000663,600,000565,000,000624,300,000638,800,000590,000,00026,000,000
Net income
-130m
L-36.06%
-32,943,0000-103,054,000-98,079,000-89,246,000-392,009,000-85,863,000-154,936,000-56,584,000-197,987,00029,000,00023,200,000137,900,000219,100,000-84,400,000-223,500,000-177,600,000-128,300,000-203,000,000-129,800,000
CFO
173m
P
-25,279,000-160,485,000-101,490,000-133,927,000-42,967,000-117,228,00028,668,000-263,201,000-487,300,000-102,193,000156,200,000146,600,000242,000,000287,000,00016,800,000-229,000,000-156,600,000-95,000,000-32,600,000173,000,000

Notes

No notes on this company yet
Write a private note on this company, for your eyes only
Add note

Profile

Orexo AB (publ), a specialty pharmaceutical company, develops and commercializes pharmaceuticals and digital therapies in the United States, European Union, the United Kingdom, and internationally. Its products include Zubsolv tablets for the treatment of opioid use disorder; Abstral for the treatment of breakthrough pain in cancer patients; and Edluar for the treatment of insomnia. The company is developing OX124 for opioid overdose; OX125 for rescue medication and opioid overdose; OX640 to treat anaphylaxis with powder-based epinephrine; and OX-MPI for the treatment of endometriosis. Its digital therapies include deprexis for the treatment of depression; vorvida for alcohol management; and modia for opioid use disorder. The company has a collaboration agreement with Abera Bioscience AB to develop nasal powder vaccines based on the AmorphOX technology. Orexo AB (publ) was founded in 1994 and is headquartered in Uppsala, Sweden.

Key people

Nikolaj Sorensen
President, Chief Executive Officer · since 2013
Fredrik Jaerrsten
Chief Financial Officer, Executive Vice President · since 2022
Robert Deluca
President of Orexo US Inc · since 2013
Cecilia Coupland
Senior Vice President, Head - Operations · since 2019
Robert Roenn
Senior Vice President, Head - Research and Development · since 2019
Edward Kim
Chief Medical Officer · since 2022
Robin Evers
Independent Director · since 2023
Staffan Lindstrand
Independent Director · since 2021
Christine Rankin
Independent Director · since 2022
Friedrich Von Bohlen Und Halbach
Independent Director · since 2024
Fred Wilkinson
Independent Director · since 2019
URL
https://orexo.se/
IPO date
Nov 09, 2005
Employees
120
Domiciled in
SE
Incorporated in
SE
Headquarters & legal address
Box 303
Uppsala, C 751 05
SE

Valuation

Title
SEK in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2025‑122024‑122023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑12
Income
Revenues
Cost of revenue
Unusual Expense (Income)
NOPBT
NOPBT Margin
Operating Taxes
Tax Rate
NOPAT
Net income
Dividends
Dividend yield
Proceeds from repurchase of equity
BB yield
Debt
Debt current
Long-term debt
Deferred revenue
Other long-term liabilities
Net debt
Cash flow
Cash from operating activities
CAPEX
Cash from investing activities
Cash from financing activities
FCF
Balance
Cash
Long term investments
Excess cash
Stockholders' equity
Invested Capital
ROIC
ROCE
EV
Common stock shares outstanding
Price
Market cap
EV
EBITDA
EV/EBITDA
Interest
Interest/NOPBT